RSRavi Shridhar

Ravi Shridhar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ravi Shridhar has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Kenneth L. Meredith

    Department of Surgical Oncology, Sarasota Memorial Hospital, Sarasota, FL, USA

    6 shared publications
  • Sarah E. Hoffe

    Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

    5 shared publications
  • Gregory M. Springett

    Gastrointestinal Tumor Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

    4 shared publications
  • Jamie Huston

    Department of Surgical Oncology, Sarasota Memorial Hospital, Sarasota, FL, USA

    3 shared publications
  • Mokenge P. Malafa

    Gastrointestinal Tumor Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

    3 shared publications
  • Pamela Hodul

    University of South Florida Morsani College of Medicine, Tampa, FL, USA ; 2 Department of Radiation Oncology, 3 Gastrointestinal Tumor Program, 4 Senior Adult Oncology Program, Moffitt Cancer Center, Tampa, FL, USA ; 5 Gastrointestinal Oncology, Sarasota Memorial Hospital, Sarasota, FL, USA

    3 shared publications

Latest Publications

  • Neoadjuvant therapy and pancreatic cancer: a national cancer database analysis

    by Ravi Shridhar, Caitlin Takahashi, Jamie Huston, Kenneth L. Meredith

    Background: We sought to examine the impact of neoadjuvant chemotherapy (NCT), single agent or multiagent chemotherapy, and neoadjuvant chemoradiation (NCRT) on survival in pancreatic cancer. Methods: Utilizing the National Cancer Database, we identified patients who underwent pancreatic resection for adenocarcinoma (2006 to 2013). Overall survival (OS) analysis was performed using the Kaplan-Meier method. Multivariable cox proportional hazard models (MVA) and propensity score matching (PSM) were developed to identify predictors of survival. For upfront surgery (UFS), OS was limited to receipt of adjuvant treatment. Results: We identified 26,563 patients who underwent pancreatic resection: UFS =23,877, NCRT =1,482, and NCT =1,204. Multiagent chemotherapy was utilized in 77% of NCT and 42% of NCRT. There was improved R0 resections associated with neoadjuvant therapy compared to UFS, however, there was no difference between NCT and NCRT. In addition, the was improved R0 with MA-NCT (PConclusions: There was improved OS associated with MA-NCT in pancreatic cancer patients compared to UFS with adjuvant therapy.


  • Anastomotic leak and neoadjuvant chemoradiotherapy in esophageal cancer

    by Ravi Shridhar, Caitlin Takahashi, Jamie Huston, Matthew P. Doepker, Kenneth L. Meredith

    Background: Anastomotic leaks (AL) cause significant morbidity after esophagectomy. Most patients receive neoadjuvant chemoradiation (NCR) prior to esophagectomy which has been associated with increase perioperative complications and mortality. We report on a comparison of AL rates in upfront surgical (UFS) and NCR patients. Methods: An esophagectomy database was queried for UFS and NCR patients treated between 1996 and 2015. Predictors of AL rate were identified using univariate and multivariate (MVA) analysis and propensity score matching (PSM). Results: We identified 820 patients (UFS, 288; NCR, 532). Overall AL rate was 5.4%. Decreased AL rate was observed in NCR patients on MVA (8.0% vs. 4.1%; P=0.02) but no difference was seen after PSM (7.7% vs. 4.2%; P=0.14). MVA of factors associated with decreased AL in UFS patients included distal esophageal tumors and body mass index (BMI) >25. Age, gender, year of surgery, histology, anastomotic location, and diabetes were not prognostic. Before PSM, MVA of NCR patients of factors associated with decreased AL revealed that only thoracic anastomosis was prognostic. However, this was not observed after PSM. MVA of factors associated with decreased AL in all patients revealed thoracic anastomosis, NCR, and BMI 25–30. After PSM, only distal esophageal tumors and thoracic anastomosis were prognostic for decreased AL. Conclusions: There is no difference in the AL rate between UFS and NCR patients. Decreased AL rate was observed in patients with distal esophageal tumors and thoracic anastomosis.


  • Accuracy of endoscopic ultrasound staging for T2N0 esophageal cancer: a National Cancer Database analysis

    by Ravi Shridhar, Jamie Huston, Kenneth L. Meredith

    Background: To determine accuracy of clinical staging of T2N0 esophageal cancer from the National Cancer Database (NCDB). Methods: The NCDB was accessed to identify patients with T2N0M0 esophageal cancer (adenocarcinoma or squamous cell carcinoma) treated between 2004–2013 that underwent esophagectomy. Pathologic staging was compared to clinical stage. Univariate (UVA) and multivariate analysis (MVA) was performed to identify factors related to pathologic upstaging using Cox proportional hazard ratio. Results: We identified 1,840 patients with T2N0 esophageal cancer who underwent esophagectomy as first line therapy. The median age was 67 years. The vast majority of patients were male and had distal adenocarcinomas. Clinical staging in was accurate pathologically in 30.7% of patients. While there was a trend for worse accuracy with increasing year of diagnosis, there rate of pT0–2N0 was stable. Tumor length >3 cm was significantly associated with tumor upstaging, while poor differentiation was significantly associated with nodal upstaging. UVA and MVA identified younger age, tumor length >3 cm, and poor differentiation were significantly associated with overall upstaging. Gender, tumor location, and tumor histology were not prognostic. Conclusions: Clinical staging for T2N0M0 esophageal cancer continues to remain highly inaccurate, however, rates of pT0–2N0 have steadily remained over 50%. Tumor length >3 cm and poor differentiation are strongly associated with pathologic upstaging.


  • Favorable perioperative outcomes after resection of borderline resectable pancreatic cancer treated with neoadjuvant stereotactic radiation and chemotherapy compared with upfront pancreatectomy for resectable cancer

    by Eric A. Mellon, Tobin J. Strom, Sarah E. Hoffe, Jessica M. Frakes, Gregory M. Springett, Pamela J. Hodul, Mokenge P. Malafa, Michael D. Chuong, Ravi Shridhar

    Background: Neoadjuvant multi-agent chemotherapy and stereotactic body radiation therapy (SBRT) are utilized to increase margin negative (R0) resection rates in borderline resectable pancreatic cancer (BRPC) or locally advanced pancreatic cancer (LAPC) patients. Concerns persist that these neoadjuvant therapies may worsen perioperative morbidities and mortality. Methods: Upfront resection patients (n=241) underwent resection without neoadjuvant treatment for resectable disease. They were compared to BRPC or LAPC patients (n=61) who underwent resection after chemotherapy and 5 fraction SBRT. Group comparisons were performed by Mann-Whitney U or Fisher’s exact test. Overall Survival (OS) was estimated by Kaplan-Meier and compared by log-rank methods. Results: In the neoadjuvant therapy group, there was significantly higher T classification, N classification, and vascular resection/repair rate. Surgical positive margin rate was lower after neoadjuvant therapy (3.3% vs. 16.2%, P=0.006). Post-operative morbidities (39.3% vs. 31.1%, P=0.226) and 90-day mortality (2% vs. 4%, P=0.693) were similar between the groups. Median OS was 33.5 months in the neoadjuvant therapy group compared to 23.1 months in upfront resection patients who received adjuvant treatment (P=0.057). Conclusions: Patients with BRPC or LAPC and sufficient response to neoadjuvant multi-agent chemotherapy and SBRT have similar or improved peri-operative and long-term survival outcomes compared to upfront resection patients.


  • Open Access

    Perioperative outcomes associated with robotic Ivor Lewis esophagectomy in patient's undergoing neoadjuvant chemoradiotherapy

    by Ravi Shridhar, Andrea M. Abbott, Matthew Doepker, Sarah E. Hoffe, Khaldoun Almhanna, Kenneth L. Meredith

    Perioperative outcomes associated with robotic Ivor Lewis esophagectomy in patient’s undergoing neoadjuvant chemoradiotherapy


  • Open Access

    Outcomes of resected pancreatic cancer in patients age ≥70

    by Thomas J. Hayman, Tobin Strom, Gregory M. Springett, Lodovico Balducci, Sarah E. Hoffe, Kenneth L. Meredith, Pamela Hodul, Mokenge Malafa, Ravi Shridhar

    Outcomes of resected pancreatic cancer in patients age ≥70


  • Resected pancreatic cancer outcomes in the elderly

    by Jessica M. Frakes, Tobin Strom, Gregory M. Springett, Sarah E. Hoffe, Lodovico Balducci, Pamela Hodul, Mokenge P. Malafa, Ravi Shridhar


  • Comparative long-term outcomes of upfront resected pancreatic cancer after preoperative biliary drainage

    by Tobin J. Strom, Jason B. Klapman, Gregory M. Springett, Kenneth L. Meredith, Sarah E. Hoffe, Junsung Choi, Pamela Hodul, Mokenge P. Malafa, Ravi Shridhar

    We evaluated whether preoperative biliary drainage was predictive of recurrence and survival among patients with resectable pancreatic cancer.